Glenmark Pharmaceuticals Ltd GLENMARK-IN:National Stock Exchange of India

*Data is delayed | INR
Last | 09/17/21 IST
518.85quote price arrow down-16.55 (-3.09%)
Volume
1,197,562
52 week range
441.70 - 690.95
Loading...
  • Open537.85
  • Day High539.45
  • Day Low517.10
  • Prev Close535.40
  • 52 Week High690.95
  • 52 Week High Date07/19/21
  • 52 Week Low441.70
  • 52 Week Low Date09/22/20

Key Stats

  • Market Cap2,015.91M
  • Shares Out282.17M
  • 10 Day Average Volume1.06M
  • Dividend2.50
  • Dividend Yield0.48%
  • Beta-
  • YTD % Change3.16

KEY STATS

  • Open537.85
  • Day High539.45
  • Day Low517.10
  • Prev Close535.40
  • 52 Week High690.95
  • 52 Week High Date07/19/21
  • 52 Week Low441.70
  • 52 Week Low Date09/22/20
  • Market Cap2,015.91M
  • Shares Out282.17M
  • 10 Day Average Volume1.06M
  • Dividend2.50
  • Dividend Yield0.48%
  • Beta-
  • YTD % Change3.16

RATIOS/PROFITABILITY

  • EPS (TTM)36.24
  • P/E (TTM)14.32
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date09/08/2021
  • Div Amount2.50
  • Split Date-
  • Split Factor-

Latest On Glenmark Pharmaceuticals Ltd

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic...
Glenn Saldanha
Chairman
V. S. Mani
Chief Financial Officer
Address
B D S Marg
Chakala, Off Western Express Highway
Andheri (E),
Mumbai
400099
India